Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityNo recent work listed

Qingqu Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3181-6865; OpenAlex author ID A5083581113. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 10

  1. VNN1 overexpression in pancreatic cancer cells inhibits paraneoplastic islet function by increasing oxidative stress and inducing β‑cell dedifferentiation. Last author DOI 10.3892/or.2023.8557↗
  2. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Last author DOI 10.1186/s12964-021-00789-w↗
  3. Dickkopf-related protein 3 alters aerobic glycolysis in pancreatic cancer BxPC-3 cells, promoting CD4+ T-cell activation and function. Co-author DOI 10.1186/s40001-021-00567-x↗
  4. Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2018.01.026↗
  5. Changes in mitochondrial function during EMT induced by TGFβ-1 in pancreatic cancer. Co-author DOI 10.3892/ol.2017.5613↗
  6. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Co-author DOI 10.1016/j.canlet.2015.12.031↗
  7. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell. Co-author DOI 10.1111/jcmm.12675↗
  8. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2012.11.015↗
  9. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. Co-author DOI 10.1007/s00432-012-1205-3↗
  10. Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. First author DOI 10.3892/ol.2012.783↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Muxing Kang · 6 shared papers, 2012–2023 · strength 0.47
  2. Wenjie Qin · 1 shared paper, 2023 · strength 0.24
  3. Yulian Wu · 5 shared papers, 2012–2018 · strength 0.23
  4. Hongbo Li · 1 shared paper, 2021 · strength 0.22
  5. Wenjie Qin · 2 shared papers, 2015–2016 · strength 0.16
  6. Dan Wu · 1 shared paper, 2021 · strength 0.15
  7. Bo Zhang · 2 shared papers, 2012 · strength 0.07
  8. Ying Chen · 2 shared papers, 2012 · strength 0.07
  9. Yizhao Zhou · 1 shared paper, 2018 · strength 0.07
  10. Wenjie Lu · 1 shared paper, 2018 · strength 0.07
  11. Qing Chen · 1 shared paper, 2018 · strength 0.07
  12. Lantian Wang · 1 shared paper, 2018 · strength 0.07
  13. Pengping Li · 1 shared paper, 2018 · strength 0.07
  14. Wen Ling Zheng · 1 shared paper, 2016 · strength 0.06
  15. Xin Dong · 1 shared paper, 2013 · strength 0.03
  16. Bin Xu · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.